Schedule 13G filing

Bain Capital Life Sciences Opportunities IV, L.P. disclosed a 10% stake in ADCT

Schedule 13G · Filed Oct 29, 2026

Bain Capital Life Sciences Opportunities IV, L.P. reported owning 10% of ADC Therapeutics SA (ADCT) (14,825,625 shares) in a Schedule 13G filed Oct 29, 2026.

A 13G is a passive stake: the holder does not plan to push for changes.

Stake

ADCT

ADC Therapeutics SA

Stake

10% stake

Disclosed: Oct 29, 2026
Source: Schedule 13G

See the filing

Share this trade

From a public Schedule 13G, linked above. Not investment advice, and not a recommendation to buy or sell.